论文部分内容阅读
目的:观察贝伐单抗联合紫杉醇加卡铂一线治疗IIIB~IV期非鳞非小细胞肺癌的临床疗效及不良反应。方法:回顾性分析哈尔滨医科大学附属肿瘤医院肿瘤内科2011年5月至2012年5月病理学确诊的IIIB~IV期非鳞非小细胞肺癌病例31例,其中12例接受贝伐单抗联合紫杉醇加卡铂方案治疗6个周期,并单药贝伐单抗进行维持治疗直至病情进展(研究组);19例接受紫杉醇加卡铂方案治疗6个周期(对照组),观察其疗效及不良反应,并进行随访。结果:研究组和对照组的中位无进展生存期分别为8.4个月和5.9个月(P<0.05),中位生存期分别为17.2个月和16.6个月(P>0.05);研究组较对照组增加的不良反应主要是高血压。结论:贝伐单抗联合紫杉醇加卡铂治疗非鳞非小细胞肺癌可延长患者的无进展生存期,且耐受性较好,具有很好的临床应用前景。
Objective: To observe the clinical efficacy and adverse reactions of bevacizumab plus paclitaxel plus carboplatin in the first-line treatment of stage IIIB to IV non-squamous non-small cell lung cancer. METHODS: A retrospective analysis of 31 patients with pathologically confirmed IIIB to IV NSCLC from May 2011 to May 2012 in our Department of Oncology, Affiliated Tumor Hospital of Harbin Medical University included 12 patients receiving bevacizumab combined with paclitaxel The carboplatin regimen was treated for 6 cycles with single-agent bevacizumab until the disease progressed (study group). Nineteen patients received the paclitaxel plus carboplatin regimen for 6 cycles (control group), and their efficacy and adverse reactions were observed , And follow-up. Results: The median progression-free survival of study group and control group were 8.4 months and 5.9 months (P <0.05), and the median survival time was 17.2 months and 16.6 months respectively (P> 0.05). The study group Adverse reactions increased compared with the control group is mainly high blood pressure. Conclusion: Bevacizumab combined with paclitaxel plus carboplatin in the treatment of non-squamous non-small cell lung cancer patients can extend the progression-free survival of patients with better tolerability and has good clinical application prospects.